Botox for migraines: waste, high cost, and low adherence

February 1, 2019

Finding the right treatment can be a real headache for migraine patients.

For those who finally try it, it doesn’t look like Botox® is much help either. 

Patients who try Botox have not responded to other conventional migraine therapies. They have struggled to find relief from acute, debilitating headaches. This study looked at 2,500 patients who were new to Botox therapy. Treatment consists of injections given in the face, head and neck by a doctor in a health care setting. 

Waste: Because of vial sizes and dosing, there is substantial drug waste. Drug waste and provider administration accounts for one-third of the drug’s $6,300 annual cost. Low adherence: Less than half of the patients completed the recommended four courses of quarterly treatments. This indicates treatment failure. High cost: The study found that Botox did not decrease total cost of care for patients with migraines. It was associated with a three-fold increase in total migraine-related costs.

Read more.

OnabotulinumToxinA (Botox® ) and Migraine: Persistence, Utilization and Expenditure within the Botulinum Toxin Drug Class (Spring 2019)

Related news

Perspectives

April 16, 2024

AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea

Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients

Perspectives

April 15, 2024

Oncology Insights: Cancer treatment is personal

Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments

Perspectives

April 15, 2024

High-Cost Therapy Profile

Detailed information about prademagene zamikeracel Topical surgical application